A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the effectiveness of chimeric antigen receptor (CAR) T cell thera…
Adding targeted radiation to chemotherapy prior to surgery may offer better control of pancreatic tumors—potentially reducing the rate of recurrence after treatment, according to a new study from UT Southwestern Medical Center. Published in Clinical Ca…
Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without these mutations, according to researchers from The Univ…
Advanced treatments, known as immunotherapies that activate T cells—our body’s immune cells—to eliminate cancer cells, have shown limited efficacy as standalone therapies for glioblastoma, the most lethal form of brain tumor. This is due to their minim…
When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that depletes B cells—the immune cells that drive MS progressi…
Scientists have revealed how certain immune cells may be quietly helping prostate cancer grow—and how blocking them could help the body fight back.
A team of researchers led by NYU Tandon School of Engineering’s Weiqiang Chen has developed a miniature device that could transform how blood cancer treatments are tested and tailored for patients.
Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell transplants, but the disease needs to be brought unde…
The innate immune system is the body’s first line of defense against pathogens and foreign substances. An essential component of this system are pattern recognition receptors, which recognize non-self RNA—such as that from viruses and bacteria—and trig…
The U.S. Food and Drug Administration has approved GSK’s autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving standard therapy.
